Compare Eli Lilly And Co (LLY) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs State Street SPDR S&P Homebuilders ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while State Street SPDR S&P Homebuilders ETF trades at $94.77 (market cap $1.49B). The key difference: Eli Lilly And Co is far larger — about 698× State Street SPDR S&P Homebuilders ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| LLY | XHB | |
|---|---|---|
Market Cap | $1.04T | $1.49B |
Volume | 3,064,878 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.28K | $121.36 |
52-Week Low | $799.57 | $94.86 |
Typical Hold Time | 93 Days | 33 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
XHB (SPDR S&P Homebuilders ETF) trades at $94.77, down 0.13% with a bearish technical outlook from moving averages. The ETF tracks homebuilder stocks facing headwinds from rising mortgage rates near 7%, though recent news highlights potential buying opportunities amid sector undervaluation. Technical indicators show neutral oscillators but bearish momentum with support at $94 and resistance at $96.
The housing market faces mixed signals with rising rates pressuring affordability, but legislative support and institutional interest suggest long-term potential. Key risks include mortgage rate volatility and economic sensitivity, while analyst coverage emphasizes sector recovery prospects. Investment appeal hinges on housing market stabilization and policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
